Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

Completed

• Conditions: Liver Transplantation

• Registration Number: NCT02995096
• Lead Sponsor: Rigshospitalet, Denmark

Brief Summary

Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an important cause of mortality for this surgical population. In addition to tumor characteristics, It has been suggested that pre-treatment and sirolimus-based immunosuppression may affect recurrence and survival. With data from the European Liver Transplant Registry (ELTR) database, the aim of this study is to investigate the impact of tumor characteristics, pre-transplant treatment and immunosuppression regimens on survival after liver transplantation for HCC.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-01
• Study First Submitted: 2016-12-14
• Study First Submitted QC: 2016-12-15
• Study First Posted: 2016-12-16
• Primary Completion: 2018-10
• Status Verified: 2019-03
• Study Completion: 2019-03
• Last Update Submitted: 2019-03-31
• Last Update Posted: 2019-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23124

Inclusion Criteria

• Hepatocellular carcinoma within transplantation criteria

Exclusion Criteria

• Disseminated disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	up to 10 year survival

Secondary Outcome Measures

Name	Time	Method
Hepatocellular carcinoma specific survival	5 year and 10 year survival